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Background: Dioscin, a typical steroid saponin, is isolated from Dioscorea nipponica Makino and Dioscorea
zingiberensis Wright. It has estrogenic activity and many studies have also reported that dioscorea plants have an
effect in preventing and treating osteoporosis. However, the molecular mechanisms underlying their effect on
osteoporosis treatment are poorly understood. Therefore, the present study aims to investigate the mechanism (s)
by which dioscin promotes osteoblastic proliferation and differentiation in mouse pre-osteoblast like MC3T3-E1
cells and human osteoblast-like MG-63 cells.
Results: We found that dioscin (0.25 μg/ml, 0.5 μg/ml, and 1.0 μg/ml) promoted MC3T3-E1 cells and MG-63 cells
proliferation and differentiation dose dependently. Western blot analysis results showed that estrogen receptor α
(ER-α), estrogen receptor β (ER-β), β-catenin and Bcl-2 protein expression increased after MC3T3-E1 cells were
treated with dioscin. Quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis indicated
that dioscin could increase the ratio of osteoprotegerin (OPG)/receptor activator of NF-κB ligand (RANKL) and
up-regulate the level of Lrp5 and β-catenin. And by RNA interference analysis, we proved that the effect of dioscin
increasing the ratio of OPG/RANKL was dependent on Lrp5 pathway. In addition, we also found that these effects
of dioscin were abolished by ICI 182, 780 (100 nM), an antagonist of ER, indicating that an ER signaling pathway
was also involved. We also found that dioscin (0.25 μg/ml, 0.5 μg/ml, and 1.0 μg/ml) induced MG-63 cells proliferation
and differentiation in a dose-dependent manner. Western blot analysis results indicated that ER-α, ER-β and β-catenin
protein expression increased after MG-63 cells were treated with dioscin.
Conclusions: The current study is the first to reveal that dioscin can promote osteoblasts proliferation and
differentiation via Lrp5 and ER pathway.
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Osteoporosis is a universal major public health problem
which is defined conceptually as a skeletal disorder char-
acterized by low bone mass, deterioration of bone tissues
and increased risk of fracture [1,2]. Bone metabolic
balance is maintained by the balance of bone resorption
and bone formation, which depends on the interactions
between osteoblasts and osteoclasts. And bone metabolic* Correspondence: sunhuijun@dlmedu.edu.cn; Mozhenliu@hotmail.com
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formation and bone resorption [1,3]. Osteoblasts, bone-
forming cells, are controlled by hormonal and local factors
such as the canonical Wnt/Lrp5/β-catenin signaling path-
way [4]. And the canonical Wnt/Lrp5/β-catenin signaling
pathway plays an essential role in bone mass accrual,
maintenance, and regulation [5]. Wnt glycoproteins bind
to the receptor frizzled (Fzd) and their co-receptor low-
density lipoprotein receptor-related protein 5/6 (Lrp5/6)
complex, leading to stabilization and accumulation of
β-catenin in the cytoplasm [5,6]. Substantial genetic data
demonstrate Lrp5 as a regulator of bone density. AndLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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multiple abnormal bone phenotypes, including osteopor-
osis-pseudoglioma (OPPG), high bone mass (HBM) and
autosomal recessive osteopetrosis [7]. β-catenin is an essen-
tial mediator of signals emanating from Lrp5 in osteoblasts
and can promote osteoblasts survival and differentiation
through both Wnt-dependent and independent events [7].
Thus, the pathways play a crucial role in bone remodeling.
Osteoporosis can occur at any age and in any racial or
ethnic group, though more common in post-menopausal
women. It is known that estrogen plays a significant role
in the regulation of bone remodeling and maintenance
of formation [8,9] and many studies have investigated
that loss of estrogen induces reduction of bone mass
and results in post-menopausal osteoporosis [8,10].
Estrogens perform their physiological effects on target
tissues through combining with estrogen receptors, and
two subtypes of estrogen receptor (ER), ER-α and ER-β,
have been identified in osteoblasts and osteoclasts.
Estrogen acts on skeleton by the two classical estrogen
receptors, both ER-α and ER-β. And several studies also
demonstrate that estrogens may prevent osteoporosis by
regulating bone formation [10,11]. Thus, to date, the
main treatment for postmenopausal osteoporosis is hor-
mone replacement therapy (HRT) [9,12]. However, com-
pliance with HRT is poor because of the increased risks
of breast and uterine cancers associated with long term
of HRT [9,12]. So newer drugs which can overcome the
concerns of HRT are of great interest to both clinicians
and patients. Statins, which are widely used for hyper-
lipidemia treatment, can promote bone formation and
suppress bone resorption [13]. And previous study has
reported that statins can also promote estrogen recep-
tors expression, but the side effects limit the use of it in
treating osteoporosis [12]. Dioscin is an active ingredient
identified in edible medicinal plants such as Dioscorea
nipponica Makino and Dioscorea zingiberensis Wright
[14]. Previous pharmacological studies have demon-
strated that dioscin not only has anti-tumor [15] and
anti-fungal activities [16], but also can regulate hyperlip-
idemia [17] and protect liver [14]. And related studies
have reported that dioscorea plants have a role for treat-
ment of osteoporosis and perform estrogen-like effects
[18,19]. Qu et al. had reported that dioscin inhibits
osteoclast differentiation and bone resorption though
down-regulating the Akt signaling pathway [20]. Statins
are specific inhibitors of 3-hydroxy-3-methylglutaryl coen-
zyme A (HMG-CoA) reductase, a rate limiting enzyme
involved in the cholesterol synthesis pathway and statins
have also been reported to possess anabolic effects on
bone [21]. In the present studies, we investigated the
mechanism by which dioscin prevents osteoporosis using
lovastatin as a positive control. We found that dioscin
promoted proliferation and differentiation of osteoblasts.And this might be related to the effects of dioscin up-
regulating ERs (ER-α and ER-β) and β-catenin protein
expression and stimulating Lrp5, β-catenin mRNA expres-
sion levels and increasing the ratio of OPG/ RANKL. Our
results, for the first time revealed the multiple working
mechanism of dioscin on the prevention and therapy of
osteoporosis.
Methods
MC3T3-E1 cells and human osteoblast-like MG-63 cells
were purchased from Insitute of Biochemistry and Cell
Biology, CAS, Shanghai, China. Dulbecco’s modified
Eagle’s medium (DMEM) was purchased from GIBCO,
USA. Fetal bovine serum (FBS) were obtained from
Tianjin Haoyang Biologicals Technology Co., Ltd.. Dioscin
with purity of over 98% was isolated from Dioscorea nip-
ponica Makino using the method reported in previous
study [22] and it was dissolved in dimethyl sulfoxide
(DMSO). Lovastatin, which was used as positive control,
was purchased from Dalian Lvzhu Biologicals Technology
Co., Ltd.. ALP activity assay kit was purchased from
Nanjing Jiancheng Bioengineering Institute, Nanjing,
China. Western & IP Cell lysate, GAPDH antibody,
BCA Protein Assay Kit and BeyoECL Plus were purchased
from Beyotine Institute of Biotechnology. Estrogen
Receptor-α (ERα), Estrogen Receptor-β (ERβ) PolyClonal
Antibody and Bcl-2 PolyClonal Antibody were purchased
from Proteintech Group, Inc (Wuhan). PrimeScript® RT
regent Kit With gDNA Eraser (Perfect Real Time), SYBR®
Premix Ex TaqTM (Tli RNaseH Plus) and RNAiso Plus
were purchased from TaKaRa Biotechnology (Dalian) Co.,
Ltd. RNAi Oligo and Lipofectamine 2000™ were pur-
chased from Invitrogen. β-catenin MonoClonal, Poly-
Clonal Antibody and ICI 182, 780 was purchased from
Santa cruz.
Cells culture
MC3T3-E1 cells and MG-63 cells were maintained in
DMEM supplemented with 10% FBS, 100 U/ml penicillin
and 100 mg/ml streptomycin. Cells were cultured at 37°C
in a humidified atmosphere of 5% CO2. This medium was
changed every two to three days.
Cell proliferation assay
Cell proliferation was evaluated with the MTT (3-dim-
ethylthiazol-2-y- [4,5]-2, 5-diphenyltetrazolium bromide)
method. MC3T3-E1 cells and MG-63 cells were seeded in
96-well culture plates and cultured overnight in an incu-
bator. The medium was removed and cells were treated
with dioscin (0.25 μg/ml, 0.5 μg/ml and 1.0 μg/ml) for
24 h, 48 h and 72 h. Then, MTT (10 μl per well, 5 mg/ml)
solution was added in each well and incubated at 37°C for
4 h. The absorbance was measured at 570 nm by the
Enzyme standard instrument.
Table 1 Nucleotide sequences of primers used for real
time PCR detection
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MC3T3-E1 cells and MG-63 cells were seeded in 24-well
culture plates. MC3T3-E1 cells and MG-63 cells were
treated with dioscin (0.25 μg/ml, 0.5 μg/ml and 1.0 μg/ml)
or lovastatin (0.04 μM) for 72 h. The cell monolayer was
gently washed twice with iced PBS. Cells were lyzed
with 0.2% TritonX-100 and the lysate was centrifuged at
14, 000 × g for 10 min at 4°C. The clear supernatant was
used for the measurement of ALP activity and total pro-
tein concentration using an ALP activity assay kit and a
BCA-protein assay kit.
Mineralization assay
The mineralization nodules were measured by von Kossa
staining. MC3T3-E1 cells were seeded in 6-well culture
plates. Then cells were treated with dioscin (0.25 μg/ml,
0.5 μg/ml and 1.0 μg/ml) or lovastatin (0.04 μM) for
72 h. The medium was removed and cells were cultured
with the medium supplemented with Vitamin C and
β-glycerol phosphate disodium salt pentahydrate at final
concentrations of 50 μg/ml and 10 mM at 37°C for
17 days. The cell monolayer was stained following the
reference [23]. The cells were fixed with 4% paraformal-
dehyde and incubated using 5% sodium thiosulfate for
30 min. Then, 2 ml of freshly prepared 1% silver nitrate
was added to wells, which were incubated under UV
light for 30 min. The wells were rinsed with distilled
water and fixed using 5% sodium thiosulfate for 2 min,
then rinsed thoroughly with distilled water to terminate
the reaction. Then, wells were redyed using 1% neutral
red for 10 min and rinsed thoroughly with distilled
water. The formed nodules were photographed with a
Canon camera. We randomly chose five views and re-
corded mineralization nodules.
Western blot analysis
The expression of ER-α, ER-β and Bcl-2 proteins was
detected by Western blot. MC3T3-E1 cells and MG-63
cells were treated with dioscin (0.25 μg/ml, 0.5 μg/ml
and 1.0 μg/ml) or lovastatin (0.04 μM) for 72 h or 24 h
and then the cell monolayer was gently washed twice
with iced PBS. The cells were prepared with 100 μl
Western & IP Cell lysate on ice for 30s, then the lysate
was centrifuged at 12, 000 × g for 10 min at 4°C. The
centrifuged supernatant was collected, and the total pro-
tein concentration was measured using a BCA-protein
assay kit with BSA as the standard. Proteins were mixed
with 6 × sodium dodecyl sulphate (SDS) sample buffer.
Equal amounts of protein (20 μg) was resolved on a 15%
SDS-polyacrylamide gel, followed by blotting to a polyvi-
nylidene fluoride (PVDF) membrane. The membrane
was blocked by 5% milk in TTBS for 2 h at 37°C. Then
the membrane was incubated overnight at 4°C with ER-α
polyclonal antibody (1:600), ER-β polyclonal antibody(1:1000), β-catenin monoclonal antibody (1:1000), β-ca-
tenin polyclonal antibody (1:1000) and Bcl-2 polyclonal
antibody (1: 1000). The following day, the membrane was
incubated with Peroxidase-Conjugated AffiniPure goat
anti-rabbit IgG (H + L) for 2 h at room temperature.
Finally, the membrane was visualized by ECL Plus as
specified by the manufacturer.
RNA extraction and quantitative reverse
transcription- polymerase chain reaction (RT-PCR)
The expressions of Lrp5, β-catenin, OPG, RANKL
mRNA were detected by RT-PCR. Then MC3T3-E1
cells were treated with various concentrations of dioscin
(0.25 μg/ml, 0.5 μg/ml and 1.0 μg/ml) or lovastatin
(0.04 μM). Total RNA was isolated using RNAiso Plus
according to the manufacturer’s instructions. The concen-
tration and purity of the RNA were determined by meas-
uring the absorbance at 260 nm and 280 nm. Total RNA
was reverse-transcribed in 10 μL of a reaction mixture
that contained gDNA Eraser Buffer, gDNA Eraser, RNase
Free dH2O and 1.0 μL total RNA according at 42°C for
2 min. PCR was carried out in a 20 μL reaction mixture
containing SYBR® Premix Ex Taq™, specific primers
(10 μM each, Table 1), ROX Referenxe DyeII, dH2O and
2.0 μL of cDNA template. The PCR were performed using
the following cycle parameters: one cycle of 95°C for 30 s,
and 40 cycles of 95°C for 5 s, 60°C for 30 s. The target
gene transcripts in each sample were normalized on the
Figure 1 Effects of dioscin on cell proliferation in MC3T3-E1 cells and MG-63 cells. MC3T3-E1 cells (A) and MG-63 cells (B) were treated
with vehicle (Control), dioscin (0.25 μg/ml, 0.5 μg/ml and 1.0 μg/ml) or lovastatin (0.04 μM) for 24 h, 48 h and 72 h. Cell proliferation was assessed
by MTT assay. Results were obtained from three independent experiments and were expressed as mean ± SD. *P < 0.05; **P < 0.01 vs Control
(Dio 24 h vs Control 24 h; Dio 48 h vs Control 48 h; Dio 72 h vs Control 72 h).
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β-catenin [25], OPG and RANKL are listed in the Table 1.
RNA interference of Lrp5 gene
The RNA duplexes targeting the sequence of mouse Lrp5
(NM_008513) and scrambled control oligonucleotide wereFigure 2 Effect of dioscin on the expression level of Bcl-2 protein in M
concentrations of dioscin (0.25 μg/ml, 0.5 μg/ml and 1.0 μg/ml) or lovastat
was examined by Western blot. Results were obtained from three indepen
vs Control.synthesized by Invitrogen. Cultured MC3T3-E1 cells were
transfected with the siRNA and the control siRNA accord-
ing to manufacturer’s instructions. Four microliters of
Lipofectamine 2000™ and 40 nM small interfering RNA or
40 nM control oligonucleotide were used for transfection.
The result of knockdown was validated by RT-PCRC3T3-E1 cells. Cells were treated with vehicle, different
in (0.04 μM) for 24 h, and then the expression level of Bcl-2 protein
dent experiments and were expressed as mean ± SD. **P < 0.01
Figure 3 Effects of dioscin on ALP activity in MC3T3-E1 cells and MG-63 cells. MC3T3-E1 cells (A) and MG-63 cells (B) were treated with
vehicle, dioscin (0.25 μg/ml, 0.5 μg/ml and 1.0 μg/ml) or lovastatin (0.04 μM) for 72 h. The lysates were used for analysis of ALP activity. Results
were obtained from three independent experiments and were expressed as mean ± SD. *P < 0.05; **P < 0.01 vs Control.
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are listed in the Table 2.
Statistics
All assays were repeated in three independent expe-
riments. The results were expressed as the mean ± SD.
Statistical analysis to compare results between groups was
conducted by one-way analysis of variance (ANOVA). All
statistical tests were 2-tailed, and P < 0.05 or P < 0.01 was
considered significant.
Results
Effects of dioscin on MC3T3-E1 cell and MG-63 cell
proliferation
The process of bone formation includes proliferation of
osteoprogenitor cells, maturation of extracellular matrixFigure 4 Effects of dioscin on mineralization in MC3T3-E1 cells. Cells w
1.0 μg/ml) or lovastatin (0.04 μM) for 72 h. The medium was removed and
and β-glycerol phosphate disodium salt pentahydrate at final concentration
nodules were analyzed by von Kossa staining. (A) Control; (B) Dio 0.25; (C)and deposition of minerals in the matrix [26]. MC3T3-E1
cells (Figure 1A, P < 0.05 or P < 0.01) and MG-63 cells
(Figure 1B, P < 0.01) were incubated with dioscin of vari-
ous concentrations and cell growth was measured with
MTT assays to evaluate the rate of cell proliferation. The
results showed that dioscin, concentration of 0.25 μg/ml,
0.5 μg/ml and 1.0 μg/ml, promoted MC3T3-E1 cells and
MG-63 cells proliferation in 48 h and 72 h significantly in
a concentration-dependent manner compared with con-
trol cells (Figure 1, P < 0.05 or P < 0.01).
Effect of dioscin on expression of Bcl-2 protein in
MC3T3-E1 cells
Bcl-2, an anti-apoptotic protein, plays an important role
in the initiation and execution of the intrinsic pathway
of apoptosis [27]. Therefore, Bcl-2 protein expressionere treated with vehicle, dioscin (0.25 μg/ml, 0.5 μg/ml and
cells were cultured with the medium supplemented with Vitamin C
s of 50 μg/ml and 10 mM at 37°C for 17 days. And the mineralized
Dio 0.5; (D) Dio 1.0; (E) Lov. **P < 0.01 vs Control.
Figure 5 Effect of dioscin on the ratio of OPG/RANKL mRNA in
MC3T3-E1 cells. MC3T3-E1 cells were treated with vehicle, different
concentrations of dioscin (0.25 μg/ml, 0.5 μg/ml and 1.0 μg/ml) or
lovastatin (0.04 μM) for 72 h, and then the expressions of OPG (A)
and RANKL (B) mRNA were examined by RT-PCR. And the ratio of
OPG/ RANKL mRNA (C) was obtained. Results were obtained from
three independent experiments and were expressed as mean ± SD.
*P < 0.05; **P < 0.01 vs Control.
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inhibitory effect of osteoblastic apoptosis in MC3T3-E1
cells. We analyzed the expression of Bcl-2 protein
following 24 h exposure to various concentrations of
dioscin by Western blot. The result showed that dioscin
increased Bcl-2 protein expression in a concentration-
dependent manner (Figure 2, P < 0.01).
Effects of dioscin on ALP activity in MC3T3-E1 cells and
MG-63 cells
Since the appearance of ALP activity is represented as an
early biochemical marker for osteoblasts differentiation
[26], we examined the ALP activity of MC3T3-E1
cells (Figure 3A, P < 0.05 or P < 0.01) and MG-63 cells
(Figure 3B, P < 0.01) in response to dioscin. We found
that dioscin treatment could result in an obvious increase
in ALP activity compared with respective control cells,
and the effect was dose-dependent.
Effect of dioscin on the mineralization in MC3T3-E1 cells
To examine the effect of dioscin on mineralization, we
evaluated whether dioscin treatment could promote the
formation of mineralization nodule in MC3T3-E1 cells.
Extracellular matrix calcium deposits for mineralized
nodule formation were stained with von Kossa and the
calcified nodules appeared black color. Mineralization by
MC3T3-E1 cells occurred within 20 days culture. Dioscin
stimulated the formation of mineralization nodule in a
concentration-dependent manner and higher concentration
(1.0 μg/ml) of dioscin or lovastatin resulted in a significant
increase compared with control cells (Figure 4, P < 0.01).
Effect of dioscin on the ratio of OPG/ RANKL mRNA in
MC3T3-E1 cells
The balance between OPG and RANKL is important to
the regulation of bone remodeling and the ratio of
OPG/RANKL mRNA expression in osteoblastic cells is
an essential factor in bone resorption [24,28]. Cells were
treated with dioscin (0.25 μg/ml, 0.5 μg/ml and 1.0 μg/ml)
or lovastatin (0.04 μM) for 72 h and then total RNA was
isolated to evaluate the effect of dioscin on the ratio of
OPG/RANKL mRNA in MC3T3-E1 cells. As shown in
Figure 5, dioscin not only obviously increased OPG
mRNA expression in MC3T3-E1 cells at concentrations
(0.5 μg/ml and 1.0 μg/ml) tested (Figure 5A), but also
obviously decreased RANKL mRNA expression at tested
concentrations (0.5 μg/ml and 1.0 μg/ml) (Figure 5B). The
effects of dioscin or lovastatin on the ratio of OPG/
RANKL mRNA expression in MC3T3-E1 cells were
shown in Figure 5C. The results clearly showed that dioc-
sin or lovastatin could increase the ratio of OPG/ RANKL
mRNA expression dramatically, suggesting that dioscin
might regulate the process of osteoblastogenesis by its
actions on OPG and RANKL expressions.Effects of dioscin on expression of ER-α and ER-β in
MC3T3-E1 cells and MG-63 cells
Dioscorea nipponica Makino and Dioscorea zingiberensis
Wright have estrogenic activity and estrogen plays an
Figure 6 (See legend on next page.)
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(See figure on previous page.)
Figure 6 Effects of dioscin on the expression levels of ER-α and ER-β proteins in MC3T3-E1 cells and MG-63 cells. MC3T3-E1 cells and
MG-63 cells were treated with vehicle, different concentrations of dioscin (0.25 μg/ml, 0.5 μg/ml and 1.0 μg/ml) or lovastatin (0.04 μM) for 72 h.
Then the expression levels of ER-α (A, C) and ER-β (A, D) proteins in MC3T3-E1 cells and the proteins expression levels of ER-α (G, H) and ER-β
(G, I) in MG-63 cells were examined by Western blot. Pretreatment of MC3T3-E1 cells with ICI 182, 780 (100 nM) for 1 h, cells were treated with
dioscin (1.0 μg/ml) for 72 h, and then the expression levels of ER-α (B, E) and ER-β (B, F) proteins were examined by Western blot. Results were
obtained from three independent experiments and expressed as mean ± SD. *P < 0.05; **P < 0.01 vs Control.
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maintenance of formation [9,19], therefore we examined
the expression levels of ER-α and ER-β in MC3T3-E1 cells
and MG-63 cells in response to dioscin by Western blot.
The results revealed that compared with control cells the
expression level of ER-α in MC3T3-E1 cells was up-
regulated significantly in a dose-dependent manner after
the cells were treated with dioscin for 72 h (Figure 6A, C,
P < 0.01). Dioscin of 1.0 μg/ml showed a significant effect
to increase the expression level of ER-β protein compared
with control cells (Figure 6A, D, P < 0.01). However, after
pretreatment by the specific ER antagonist ICI 182, 780
for 1 h, the expression of ER-α (Figure 6B, E, P < 0.05) and
ER-β (Figure 6B, F, P < 0.01) protein was reduced com-
pared with control cells, and the effect of dioscin up-
regulating ER-α and ER-β protein level in MC3T3-E1 cells
decreased significantly compared with dioscin group cells
(Figure 6B, E and Figure 6B, F, P < 0.01). And our results
also indicated that dioscin could up-regulated obviously
the protein expression levels of ER-α (Figure 6G, H,
P < 0.01) and ER-β (Figure 6G, I, P < 0.01) in MG-63 cells.
Therefore, our results demonstrate that ER-pathway is in-
volved in dioscin-mediated effects on osteoblasts prolifer-
ation and differentiation.
Effect of dioscin on expression of Lrp5 and β-catenin
mRNA levels in MC3T3-E1 cells
Lrp5, a critical co-receptor for Wnt signaling pathway,
has been identified as an important contributor to bone
health. β-catenin acts downstream of Lrp5 and also plays
an important role in bone formation [26,29]. Therefore,Figure 7 Effects of dioscin on the expression levels of Lrp5 and β-cat
dioscin (0.25 μg/ml, 0.5 μg/ml and 1.0 μg/ml) or lovastatin (0.04 μM) for 48
examined by RT-PCR. Results were obtained from three independent experimwhether this pathway is involved in the effects of dioscin
on osteoblasts was detected. Cells were treated with vari-
ous concentrations of dioscin or lovastatin for 48 h.
Total RNA was isolated to study the effect of dioscin on
Lrp5 and β-catenin mRNA expression levels in MC3T3-E1
cells. As shown in Figure 7, compared with control
group, dioscin not only increased Lrp5 mRNA expression
significantly at all concentrations (0.25 μg/ml, 0.5 μg/ml
and 1.0 μg/ml) (Figure 7A, P < 0.05 or P < 0.01), but also
up-regulated β-catenin mRNA expression level obviously
at concentrations of 0.5 μg/ml and 1.0 μg/ml (Figure 7B,
P < 0.01). And the results also clearly demonstrated that
lovastatin (0.04 μM) could induce a significant up-
regulation on the expression levels of Lrp5 and β-catenin
mRNA in MC3T3-E1 cells (P < 0.05 or P < 0.01).
Effects of dioscin on expression of β-catenin protein in
MC3T3-E1 cells and MG-63 cells
Then we examined the expression levels of β-catenin
protein in MC3T3-E1 and MG-63 cells in response to
dioscin treatment by Western blot. The results revealed
that compared with their respective control cells, the
expressions levels of β-catenin in MC3T3-E1 cells
(Figure 8A, P < 0.01) and MG-63 cells (Figure 8B, P < 0.01)
were up-regulated significantly in a dose-dependent man-
ner after the cells were treated with dioscin for 72 h.
The stimulating activity of dioscin on the ratio of OPG/
RANKL mRNA was dependent on the Lrp5 pathway
Then transfection with Lrp5-siRNA was used to prove
that the effect of dioscin on the ratio of OPG/RANKLenin mRNA in MC3T3-E1 cells. MC3T3-E1 cells treated with vehicle,
h. The expression levels of Lrp5 (A) and β-catenin (B) mRNA were
ents and were expressed as mean ± SD. *P < 0.05; **P < 0.01 vs Control.
Figure 8 Effects of dioscin on expression of β-catenin protein in MC3T3-E1 cells and MG-63 cells. MC3T3-E1 cells and MG-63 cells were
treated with vehicle, different concentrations of dioscin (0.25 μg/ml, 0.5 μg/ml and 1.0 μg/ml) or lovastatin (0.04 μM) for 72 h. Then the expression
levels of β-catenin proteins in MC3T3-E1 cells (A) and MG-63 cells (B) were examined by Western blot. Results were obtained from three independent
experiments and expressed as mean ± SD. **P < 0.01 vs Control.
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transiently transfected with Lrp5-siRNA and control
vector. The cells transfected with Lrp5-siRNA had an
obvious reduction in the Lrp5 mRNA as demonstrated
by RT-PCR (Figure 9A). To determine the effect of
dioscin on the ratio of OPG/ RANKL in the cells with
reduced Lrp5, we treated Lrp5-siRNA and control vectorFigure 9 The effect of dioscin increasing the OPG/RANKL mRNA ratio
interference against Lrp5. MC3T3-E1 cells grown in regular medium were t
was extracted and analyzed by RT-PCR. (B) The effect of dioscin-increased
Lrp5-siRNA was abolished. (C, D, E) Dioscin increased OPG/RANKL ratio wa
dioscin (1.0 μg/ml) for 72 h, and then the expression of Lrp5, OPG and RANKL
independent experiments and were expressed as mean ± SD. **P < 0.01 vs Cocells with 1.0 μg/ml of dioscin and determined the ratio
of OPG/ RANKL by RT-PCR. As shown in Figure 9,
dioscin treatment could not up-regulate the expression
of Lrp5 mRNA (Figure 9B) and OPG mRNA (Figure 9C),
decrease the expression of RANKL mRNA (Figure 9D)
and increase OPG/ RANKL ratio (Figure 9E) in Lrp5-
siRNA cells as in normal MC3T3-E1 cells (P < 0.01),was dependent on Lrp5. (A) Reduced Lrp5 expression by RNA
ransfected with Lrp5-siRNA construct and control vector. Total RNA
Lrp5 expression level in MC3T3-E1 cells which were transfected with
s dependent on Lrp5 pathway. Cells were treated with vehicle and
mRNA were examined by RT-PCR. Results were obtained from three
ntrol; ##P < 0.01 vs Dio group.
Figure 10 (See legend on next page.)
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Figure 10 Effects of ICI 182,780 on dioscin-induced ALP activity, Lrp5 and β-catenin mRNA expressions and ratio of OPG/RANKL mRNA
in MC3T3-E1 cells. MC3T3-E1 cells were treated with vehicle and dioscin (1.0 μg/ml) in the presence or absence of ICI 182, 780 (ICI). (A) ALP
activity. Cell lysates were used for ALP activity measurement by an ALP activity assay kit. Results were obtained from three independent experiments
and were expressed as mean ± SD. (B) Lrp5 mRNA expression level. (C) β-catenin mRNA expression level. (D) OPG mRNA expression level. (E) RANKL
mRNA expression level. (F) OPG/RANKL mRNA ratio. (G) β-catenin protein expression level. Results were obtained from three independent experiments
and expressed as mean ± SD. *P < 0.05; **P < 0.01 vs control. # P < 0.05; ## P < 0.01 vs Dio group.
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mRNA ratio was partially dependent on Lrp5 pathway.
The inducing effects of doscin on ALP activity, Lrp5,
β-catenin, OPG/ RANKL gene expressions and β-catenin
protein expression in MC3T3-E1 cells were dependent on
the ER pathway
In order to determine whether the stimulatory effects of
dioscin on ALP activity, Lrp5, β-catenin, OPG/RANKL
gene expressions and β-catenin protein expressions were
dependent on the ER signaling pathway, MC3T3-E1 cells
were co-incubated with ICI 182,780 (100 nM), an antag-
onist of both ER-α and ER-β. Then ALP activity was
determined by ALP activity assay kit and Lrp5, β-catenin
and OPG/RANKL gene expression were analyzed by
RT-PCR. β-catenin protein expression was analyzed by
Western blot. As shown in Figure 10A, 1.0 μg/ml of
dioscin significantly increased MC3T3-E1 cell ALP activ-
ity (P < 0.05) and the stimulatory effect was abolished by
co-treatment with ICI 182,780. Similarly, the stimulatory
effects of 1.0 μg/ml dioscin on Lrp5 (Figure 10B), β-catenin
(Figure 10C), OPG (Figure 10D) and RANKL (Figure 10E)
as well as on the ratio of OPG/RANKL (Figure 10F)
were also abolished by co-treatment with ICI 182,780.
The effect of dioscin obviously increasing β-catenin pro-
tein expressions in MC3T3-E1 cell was also abolished
by co-treatment with ICI 182,780 (Figure 10G). These
results indicate that the stimulatory effects of dioscin on
osteoblastic functions were ER-dependent.
Discussion
This study evaluated the osteoprotective effects and
mechanism of actions of dioscin in mouse pre-osteoblast
like cells MC3T3-E1. We have demonstrated that dios-
cin is capable of promoting proliferation, differentiation
and mineralization of osteoblasts and inhibiting osteo-
blasts apoptosis. ALP, representative of early stage of
osteoblast differentiation markers, is known to be import-
antly involved in the initiation of mineralization during
bone formation. And ALP activity is a critical indica-
tor of osteoblasts differentiation and osteogenic properties
[30,31]. Bcl-2 plays a crucial anti-apoptotic function role
[27]. In our results, we revealed that dioscin could signifi-
cantly increase ALP activity and up-regulate Bcl-2 expres-
sion level in MC3T3-E1 cells. Because MG-63 cell line hasa similar antigenic prolife to that in primary cultured
human osteoblasts from human bone tissue sections
[32,33], therefore, we also detected the promoting effects
of doscin on osteoblasts by using this human osteoblast-
like cells. And the results indicated that dioscin could also
promote the proliferation and differentiation of MG-63
cells significantly.
OPG and RANKL are osteoblast-derived proteins piv-
otal to the regulation of bone mass and play opposing
effects on osteoclasts [34,35]. OPG, a decoy receptor for
the RANKL, is expressed by osteoblasts. RANKL inter-
acts with RANK on osteoclasts to stimulate bone resorp-
tion by increasing osteoclast differentiation, activation
and survival. OPG can also bind to RANKL but prevents
RANKL-RANK interaction [36], thus, inhibits bone re-
sorption [35,36]. Therefore, the OPG/RANKL ratio is crit-
ical to the coupling of bone resorption to bone formation
[35]. We found that OPG mRNA expression could be in-
creased significantly (Figure 5A) and RANKL mRNA ex-
pression could be decreased significantly (Figure 5B) when
MC3T3-E1 cells were exposed to various concentrations
of dioscin. Therefore, we conclude that dioscin could pro-
mote osteoblasts proliferation by up-regulated the OPG
expression and inhibit ostoclasts differentiation by de-
creased the RANKL expression.
ER signaling pathways play a crucial role in the bone
remodeling, the development and maintenance of the
skeleton [8,37,38]. Two ERs (ER-α and ER-β) have been
reported to be differently expressed during osteoblast
differentiation. And the view has also been accepted
widely that estrogen acts on the bone cells through the
classical ER-α and ER-β [10,38], and deficient of ER-α
expression can result in osteoporosis [39]. And the human
ER-β gene has also been reported to be associated with
the risk of osteoporosis and bone mineral density (BMD)
[40]. So ERs plays a significant role in the proliferation
and differentiation of the osteoblasts, and ERs may be an
important molecular target for treatment of osteoporosis
and maintaining bone formation. In the present study, we
have investigated that dioscin can up-regulate dose-
dependently the expression of both ER-α and ER-β
proteins (Figure 6, P < 0.01) in MC3T3-E1 cells. We
also found that dioscin has the same effects in human
osteoblast-like MG-63 cells. ICI 182,780 (Faslodex)
from AstraZeneca (Cheshire, United Kingdom) is
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was designed to be devoid of estrogen agonist action in
both in vivo and in vitro models [41,42]. It can abolish es-
trogen agonist activity by competing with endogenous es-
trogen for ERs presented in the nuclei of estrogen
responsive tissues [41,42]. As Figure 6B, E and Figure 6B,
F shown, the expressions of ER-α (P < 0.05) and ER-β (P <
0.01) were blocked by ICI 182,780. At the same time, the
effects of dioscin which stimulated ER-α and ER-β protein
expression can be blunted by ICI 182, 780 (P < 0.01). And
we found that the effects of doscin increasing ALP activity
and the ratio of OPG/RANKL were also inhibited by ICI
182, 780. Therefore, we argue that dioscin may promote
MC3T3-E1 cells proliferation and differentiation via the
ER signaling pathway.
Wnt/β-catenin signaling pathway, is also critical in
bone formation and maintenance of bone mass [43,44].
However, Lrp5, a critical co-receptor for Wnt signaling
pathway and upstream of β-catenin, has been identified
as an important contributor to bone health. And Lrp5
was observed to be associated with human HBM disease
and OPPG syndrome characterized primarily by low
bone mass through genetic studies of human bone
abnormalities, Lrp5 knockin mice and Lrp5-deficient
mice [26,29]. β-catenin signaling pathway plays an im-
portant role in bone formation in vivo [45,46] and
deletion of the β-catenin gene can prevent osteoblast
proliferation and differentiation in vitro [47]. Present
study revealed that dioscin could increase obviously
the expression level of Lrp5 mRNA, β-catenin mRNA
and β-catenin protein in MC3T3-E1 cells. However,
the effects of dioscin could be inhibited by ICI 182,
780. Therefore, our study suggests that the effect of dioscin
regulating the expression level of Lrp5 and β-catenin might
also be dependent on the ER signaling pathways.
Since Lrp5 also plays an important role in bone forma-
tion, then we will question the hypothesis: whether dios-
cin increases the ratio of OPG/ RANKL mRNA is
dependent on Lrp5 signaling pathway? To demonstrate
the hypothesis, the present study applies RNA interfer-
ence to make Lrp5 gene in MC3T3-E1 cells be knocked
down, then the cells were treated by dioscin (1.0 μg/ml)
for 72 h. We found that the ratio of OPG/RANKL
mRNA could not be up-regulated by doscin as in
normal cells anymore. Thus, we conclude that dioscin
performs its function, increasing significantly the ratio
of OPG/RANKL mRNA, via Lrp5 signaling pathway
partially.
In conclusion, the present study clearly demonstrated
that dioscin not only could promote MC3T3-E1 cells
proliferation and differentiation, but also could promote
human osteoblast-like MG-63 cells proliferation and differ-
entiation. And dioscin directly stimulated the expression
level of Lrp5, β-catenin and increased the ratio of OPG/RANKL. And these effects of dioscin might be dependent
on ER pathway and Lrp5 pathway in MC3T3-E1 cells.
Therefore, our results provide a new insight into the
mechanisms of dioscin on prevention and treatment
of osteoporosis.
Conclusions
Our study provides the evidence to support the use of dios-
cin as an effective candidate for osteoporosis. Therefore,
the results of our study indicated that dioscin has potential
effects in prevention and treatment of osteoporosis.
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